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Abstract 
Pregabalin is the first-line treatment for neuropathic pain (NeP) in humans. Dogs with Chiari-
like malformation and syringomyelia (CM/SM) associated with NeP could benefit from pregabalin. 
The aim of this study was to evaluate the efficacy of pregabalin for NeP in dogs with CM/SM. Eight 
dogs with symptomatic CM/SM were included in a double-masked, randomised, crossover placebo–
controlled clinical trial. All dogs received anti- inflammatory drugs as base-line treatment during 
placebo or pregabalin phase of 14 ± 4 days each. Analgesic efficacy was assessed with a daily 
numerical rating scale (NRS) recorded by dog owners (0–10, 10 = worst pain) and quantitative sensory 
testing at baseline, placebo and pregabalin phases. Blood samples were collected to report pregabalin 
exposure and to assess renal function. 
Daily NRS scores recorded by dog owners in the pregabalin group were lower than in the 
placebo group (P = 0.006). Mechanical thresholds were higher with pregabalin compared to baseline 
or placebo (P = 0.037, P < 0.001). Cold latency at 15 °C was prolonged on the neck and humeri with 
pregabalin compared to baseline (P < 0.001 for both) or placebo (P = 0.02, P = 0.0001). Cold latency 
at 0 °C was longer on pregabalin compared to baseline and placebo (P = 0.001, P = 0.004). There was 
no pregabalin accumulation between first and last dose. This study demonstrates the efficacy of 
pregabalin for the treatment of NeP due to CM/SM on daily pain scores recorded by dog owners. 
Pregabalin significantly reduced mechanical hyperalgesia, cold hyperalgesia (0 °C) and allodynia 
(15 °C) compared to placebo. Pregabalin was non-cumulative and well tolerated with occasional mild 
sedation. 
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Introduction 
Chiari-like malformation and syringomyelia (CM/SM) is a disease complex described in dogs, 
which can cause clinical signs suggestive of central neuropathic pain (NeP; Rusbridge and Jeffery, 
2008). Clinical signs such as vocalisation, avoidance and perhaps scratching behaviour in response 
to noxious and non-noxious stimuli have been suggested to represent hyperalgesia and allodynia 
respectively (Nalborczyk et al., 2017; Plessas et al., 2012; Rusbridge and Jeffery, 2008). 
The assessment of effective analgesics to manage NeP in dogs has been limited and has focused 
on either assessment of the cardinal clinical signs of CM/SM or on quality of life (QoL) scoring 
(Plessas et al., 2012; Plessas et al., 2015). The use of quantitative sensory testing (QST) could help 
to evaluate more objectively the efficacy of treatment, may increase sensitivity to discriminate between 
NeP-affected vs unaffected dogs and help to identify the possible mechanisms involved (Backonja et al., 
2009). 
Current treatment for NeP disorders is limited by a lack of clinically tested, effective 
analgesics to provide sufficient respite for affected dogs and humans (Finnerup et al., 2015; Moore, 
2016). In humans with NeP, pregabalin and amitriptyline are recommended as first line therapy 
(NICE CG 173, 20131). In veterinary medicine, some data suggest that gabapentin and potentially 
pregabalin might improve NeP signs associated with CM/SM (Plessas et al., 2012; Plessas et al., 
2015). 
The pharmacokinetics of pregabalin have been investigated in healthy laboratory dogs after 
oral administration of a single 4 mg/kg dose (Salazar et al., 2009). The terminal half-life of 
approximately 7 h, suggests that two administrations per day may be appropriate, unlike gabapentin, 
which has a terminal half-life of 3 to 4 h and requires its administration three times a day (KuKanich, 
2013). Dewey et al. (2009) evaluated long-term pregabalin at 3 to 4 mg/kg three times daily for 
idiopathic epilepsy as an add-on to phenobarbital and/or potassium bromide administration. Increase in 
sedation or ataxia levels were the only side-effects reported. There are currently, however, no 
published randomised controlled trials evaluating the drug exposure and efficacy of pregabalin in the 
treatment of canine NeP. 
The aim of this study was to evaluate the efficacy of pregabalin for treatment of canine NeP 
in a randomised placebo-controlled double-masked study. We hypothesised that pregabalin would 
demonstrate a superior effect on pain assessment outcomes compared to baseline and placebo. The 
primary efficacy endpoint was the ‘daily pain assessment’ with numerical rating scale (NRS; score 
from 0 [no pain] to 10 [worst pain]) recorded by dog owners and the secondary endpoint was the QST. 
  
Materials and methods 
The study was performed as a double masked, randomised, crossover placebo-controlled trial. 
Client-owned dogs with clinical signs compatible with NeP (at least cervical hyperaesthesia or 
spontaneous vocalisation) and with CM ± SM confirmed by Magnetic Resonance Imaging (MRI) scan 
performed within the preceding 6 months were included. The definition of CM and SM was made 
according to the British Veterinary Association Scheme for CM and SM2 as grade 2 for both. 
A recent MRI was necessary to ensure that the clinical signs were not related to other painful 
myelopathies such as intervertebral disc disease. Images followed the same guidelines.2 A European 
Diplomate in Veterinary Neurology performed a neurological examination on the first visit and 
confirmed the diagnosis of CM/SM being the only clinically relevant diagnosis. All dogs received non-
steroidal anti-inflammatory drugs (NSAIDs) for at least 2 days prior to the start of the trial. 
Dogs that presented a heart murmur or heart disease could be included, but heart failure was 
an exclusion criterion. Dogs with chronic kidney disease in IRIS stage 3 or higher (serum creatinine 
>180 µmol/L, International Renal Interest Society3), were excluded from the study. Although 
previous pregabalin treatment was an exclusion criterion, previous treatment with gabapentin was 
accepted as long as the last dose had been given at least 5 days before starting the trial. If additional 
treatment for other conditions was necessary, additional drugs could be administered with the 
exception of those referenced in Appendix A. Dogs with dermatological conditions were excluded 
following a dermatological exam performed during the first visit. 
Any adverse event, even unrelated with the administration of the drug or the procedures 
performed during the trial, was followed up, but the dog was excluded from the study. Dogs were also 
withdrawn if the owners were unable to comply with the daily dosing routine or were unable to attend 
any visit. 
Study design 
The study consisted of a baseline phase with NSAIDs as sole treatment and two periods during 
which the dogs additionally received pregabalin (5 mg/kg twice daily, orally) or placebo for 14 ± 4 
days each. Animals were randomly assigned (block randomisation, Excel, Microsoft Office 2016) 
to one of two sequences (pregabalin-placebo or placebo-pregabalin) as displayed in Fig. 1. The baseline 
treatment ensured some analgesia was provided for the two-week period to avoid ethical or welfare 
constrains during the placebo treatment phase. 
The study was carried out under the European Directive 2010/63/EU on the protection of 
animals used for scientific purposes (Project License PPL 70 / /8152). The study was monitored to 
Good Clinical Practice standards, according to VICH GL94 and was approved by the Royal Veterinary 
College Ethics and Welfare Committee on the 29th August 2013 (URN 2013 1243). 
Pregabalin and placebo administration 
The pregabalin formulation was the oral solution Lyrica (20 mg/mL, bottle of 473 mL Pfizer). 
The placebo formulation was reverse-engineered according to Good Manufacturing Practices5 from 
qualitative information available about the vehicle used in Lyrica. Dog owners and the investigator 
remained masked to the treatment. The administration of the first dose occurred during Visit 1 (Fig. 
1). At 24 h after the first dose, the dogs continued with the same treatment at home twice daily for 14 ± 4 
days until Visit 2. Dog owners recorded each dose given and the time of administration on a diary to 
confirm the compliance. 
The treatments were switched over at Visit 2 (Fig. 1). A dispenser administered the 
medication in the hospital so the primary investigator remained masked to the treatment during 
treatment switch. The dogs that were receiving pregabalin during period 1, received their last dose of 
pregabalin followed by the first dose of placebo 24 h thereafter. 
Alternatively, the dogs that were receiving placebo during period 1, received their first dose of 
pregabalin followed by another dose 24 h thereafter. After Visit 2, dogs continued with the second 
treatment twice daily for 14 ± 4 days, until Visit 3. The dogs were officially signed off the study after 
the last sample collection of Visit 3 and transferred to the care of their usual veterinarian. If 
efficacious, open-label pregabalin treatment could be continued by the primary veterinarian. 
Efficacy assessment 
Daily pain scores (NRS) recorded by dog owners 
During the two periods of medication, dog owners recorded in a booklet a pain score with NRS 
at the end of each day of medication at home. They were assessing spontaneous vocalisations, phantom 
scratching episodes and exercise impairment (Plessas et al., 2012) to score the pain severity daily 
(from 0 [no pain] to 10 [worst pain]) after being previously instructed how to perform it. 
The primary investigator (SSM) performed the physical and neurological examinations and 
QST. The dogs stayed in hospital for at least 24 h at Visit 1, Visit 2, and Visit 3, during which the 
following parameters were recorded. 
Quantitative sensory testing 
The somatosensory function was then assessed with QST following the Sensory Threshold 
Examination Protocol (STEP) described previously (Sanchis-Mora et al., 2017). The stimuli were 
applied on the skin of six body areas (BA) in a randomised order in unrestrained dogs. A threshold was 
obtained when the animal responded according to previously used criteria (Sanchis-Mora et al., 2017) 
with the addition of phantom scratching. The body areas tested were lateral neck, humeri and tibias 
(bilaterally; Appendix BB). It was necessary to clip a 1.5 × 1.5 cm square of hair for each BA. The 
STEP consisted of the evaluation of the sensory modalities briefly explained below. Von Frey filaments 
(Bioseb) were used for tactile sensory thresholds (TST) and tactile allodynia. The 50% response 
technique described by Sanchis-Mora et al. 2017) was used. Mechanical stimulus was applied with an 
algometer (ProdPro, Topcat Metrology Ltd). Heat stimulus was applied using a handheld thermal 
probe (HotPro, Topcat Metrology Ltd). Both the mechanical thresholds (MT) and heat thresholds (HT) 
were measured in triplicate for each BA. Cold / /cool stimuli were applied using a handheld thermal 
probe (NTE-2A, Physitemp Instruments) set at 0 ± 0.2 °C and 15 ± 0.2 °C, respectively. The latency 
(measured in s) between cold/cool application and the time at which the animals responded to the probe 
was recorded. The measurements were performed in triplicate for each BA and for each temperature. 
Blood and urine samples  
At each visit, 1 mL of blood was taken for plasma pregabalin concentration measurement at 
baseline (0 h, time of treatment administration), at 90 ± 9 min post-dose administration (presumed time 
of peak plasma concentration, (Salazar et al., 2009)) and at 12 h ± 72 min post-dose administration 
(trough concentration; Fig. 1). Blood samples were taken through a preplaced peripheral catheter 
(Introcan IV catheter, Braun Vetcare) according to the method from Elliott et al. (2010). The samples 
were transferred into EDTA tubes, then centrifuged at 1000 g for 10 min (Jouan C3i-CR3I 
Multifunction Centrifuge, Thermo). Two aliquots of at least 150 µL of EDTA plasma were separated 
and stored at −80 °C within 6 h after collection. 
Plasma pregabalin concentration was measured by liquid chromatography tandem mass 
spectrometry using a validated method (Appendix C). Plasma creatinine was measured on each visit 
using a calibrated portable machine (creatinine cartridges, ISTAT-1, VetScan Abaxis). A urinary 
sample was collected by free catch for urinary dipstick analysis (Siemens Multistick Siemens 
Healthcare) and urinary specific gravity. 
Statistical analysis  
Sample size calculation6 estimated that nine dogs would be required to demonstrate an 
increase 3 N (standard deviation, SD = 1.9) in MT in the neck area with 90% power and 5% type I error 
rate. The mean and SD were based on previous non-published data testing in asymptomatic and 
symptomatic CM/SM dogs.  
Baseline, pregabalin and placebo were considered as three phases for statistical comparisons. 
Data were analysed using a commercial statistical software (SPSS 21, IBM and R7). For continuous 
data, normality of distribution was verified by Kolmorov–Smirnov’s test and by visual assessment of 
Q–Q plots and histograms. 
Linear mixed models were used to assess effects of treatment period (baseline, pregabalin and 
placebo), BA and their interaction for TST, MT and HT, and dog identification was considered as a 
random effect. 
Cold thresholds at 0 (0 se latency or >1 s latency) and 15 °C (censored at 60 s) were analysed 
with generalized linear mixed effects model and mixed effects Cox model, respectively, with the same 
fixed and random effects as above. Additionally, linear mixed effects model was used to assess the 
effects of pregabalin versus placebo and number of days within treatment on owner-recorded daily NRS 
scores. 
It was not possible to test the sequence effect due to the small sample size. Post hoc comparisons 
were made when appropriate using the Fisher’s Least Significant Difference (LSD). The mean peak 
and trough plasma concentrations after the first and last dose were compared with a paired t-test to 
evaluate an increase in plasma concentration by the end of the period. 
Results 
Descriptive demographics, clinical data and neurological exam 
Nine Cavalier King Charles Spaniels (four males and five females) were recruited for the 
study from February 2016 to August 2016 (Fig. 2). The median age was 6 years old (range, 1.1–9 
years) and the median bodyweight was 9.6 kg (range, 6.6–13.8 kg). All dogs presented with cervical 
hyperaesthesia on palpation and five dogs showed scratching behaviour, either phantom scratching or 
making contact with the skin without evidence of skin/ear disease. 
The baseline NSAID was meloxicam 0.05 mg/kg once daily for seven dogs and carprofen 
2 mg/kg once daily for two dogs. Two dogs were previously treated with gabapentin at 10 mg/kg twice 
daily. Gabapentin administration was stopped between 6 and 10 days before starting the trial. These 
two dogs were randomly allocated to placebo phase during the first period. 
Six dogs had a heart murmur. One had cardiac investigation due to bradyarrhythmia. The 
electrocardiogram revealed benign second-degree auriculo-ventricular block, Mobitz type II and 
echocardiography revealed a trivial mitral valve regurgitation and mild tricuspid regurgitation. None 
of the dogs received additional medication except one dog (ocular treatment with fusidic acid twice 
daily). 
Clinical history and neurological examination results are summarised in Appendix D. Urine 
analysis and plasma creatinine values were within normal limits for all dogs. 
One dog dropped out of the study at day 7 of the first period due to an ailment unrelated to the study 
(Fig. 2). This dog developed haemorrhagic diarrhoea at the same time as other dogs in the household. 
Nevertheless, this dog was subsequently excluded as the treatment with NSAIDs may have been 
contraindicated. This dog was receiving placebo during the first period and its data were excluded 
from the statistical analysis. Sedation was reported in two other dogs. No other side effects were 
reported. 
Dog owner daily pain assessment 
The daily pain scores (NRS) recorded by dog owners was significantly lower during 
pregabalin treatment phase (mean 3.17 ± SD 2.3 units) compared to the placebo phase (mean 4.24 ± SD 
2.4 units, P =  0.006, Fig. 3). Number of days within treatment did not significantly affect daily NRS 
scores recorded by dog owners (P =  0.470). 
Quantitative sensory testing 
For each of the QST modalities, there was main effect of body area (P < 0.001) and treatment 
phase effect for TST (P = 0.002), MT (P = 0.001), CL0 (P = 0.001) and CL15 (P = 0.001), but not 
for HT (P = 0.094). However, the interaction between BA and treatment was not statistically 
significant in any of the QST modalities (P > 0.05) except CL15 (P = 0.005; see below). 
On post hoc comparison, baseline and pregabalin TST were significantly higher than for the 
placebo (P = 0.001 and P = 0.005 respectively). Pregabalin TST were not significantly different 
from baseline P = 0.567. MT for pregabalin were significantly higher than baseline and placebo 
(P = 0.037 and P < 0.001, respectively) overall (represented as mean ± SD in Fig. 4), whereas 
placebo and baseline were not different (P = 0.097). 
Under pregabalin treatment, CL0, was significantly longer from baseline (P = 0.001) and 
placebo (P = 0.004). Placebo and baseline phases were not different from each other (P = 0.686; Fig. 
5). For CL15, the interaction between treatment phase and BA was statistically significant 
(P < 0.005). Neck and humeri showed longer latencies on pregabalin compared to baseline (P < 0.001 
for both) or placebo (P = 0.02, P = 0.0001, respectively; Fig. 6). Latencies were longer during 
baseline than placebo for humeri (P = 0.001) but not the neck (P = 0.167). 
Pregabalin plasma concentration 
Peak plasma concentration at first dose (mean 4128 ng/mL, range 2420–5538 ng/mL) and at 
last dose (mean 4669 ng/mL, range 3704–6023 ng/mL) were not significantly different (P = 0.153). 
Trough plasma concentration (12 h after peak) at first dose (mean 1047 ng/mL, range 541–
1844 ng/mL) and at last dose (mean 1075 ng/mL, range 413–2381 ng/mL) were not significantly 
different (P = 0.769). Pregabalin was undetectable during the placebo phase. 
Discussion 
This is the first randomised controlled trial reporting the efficacy of pregabalin in dogs with 
NeP. Daily NRS scores recorded by dog owners were significantly lower during pregabalin 
treatment phase compared to placebo. Pregabalin also improved mechanical hyperalgesia and cold 
allodynia as defined by Allchorne et al. (2005), compared to placebo and baseline. 
In this study, the daily NRS assessment recorded by dog owners appeared to be a solid 
parameter. Longitudinal data do not rely on a single time point as for QST evaluation. Daily scoring 
therefore nullifies the bias of assessment at isolated points in time in the context of fluctuating clinical 
signs (Colloca et al., 2016). Similarly, in human clinical trials, pregabalin efficacy in peripheral 
neuropathy has been evaluated with success using patients’ daily pain scores (Jenkins et al., 2012). 
We cannot exclude that other degenerated clinical problems, even if not demonstrated on MRI scans, 
could have also improved with pregabalin, and therefore improved dogs’ mobility. The sample size 
calculation was based on MT data (single measurement), as there was not preliminary data on daily 
NRS pain assessment (repeated measures at home). Further significant changes could have been 
evidenced if we had more dogs included, especially when testing for interactions. For example, to 
demonstrate that NRS was significantly different between placebo and pregabalin treatments on a 
single day, post hoc sample size calculation recommended 13 dogs. We only demonstrated a difference 
of pregabalin over placebo for the overall duration of treatment with the current sample size. 
Based on the response to pregabalin on the affected areas (neck and humeri) this study suggests 
that CM/SM dogs presenting clinical signs of NeP had mechanical hyperalgesia and cold hyperalgesia 
and allodynia. Pregabalin and gabapentin are efficacious if there is central sensitisation and nerve 
damage is present (Patel and Dickenson, 2016). Visual inspection of the plotted data suggested a large 
improvement, especially for CL15 in both, humeri and neck. Reduction of cold allodynia at 15 °C 
with pregabalin was the clearest result, consistent with previous findings in rats with NeP (Lau et al., 
2013). Pregabalin has been shown to decrease hyperalgesia and allodynia for cold, brush and 
mechanical testing in small cohort of humans with NeP (Attal et al., 1998; Dirks et al., 2002). 
Although there was a treatment effect on CL0, there were no differences on the interaction with BA. 
HT thresholds showed no differences between treatment phases and baseline, suggesting HT 
may not be a sensitive test for CM/SM dogs. Another study in dogs with spinal cord injury found a lack 
of thermal sensation compared to control dogs (Gorney et al., 2016). Human patients with SM showed 
impairment of thermal sensation, however, those presenting evoked and spontaneous pain had different 
QST profiles (Hatem et al., 2010). This may be also occurring in dogs with CM/SM. 
There is no reported therapeutic window for the analgesic effect of pregabalin in people or in 
dogs with NeP, just a therapeutic range for seizure control in man (Arroyo et al., 2004; Berry and 
Millington, 2005). The mean steady-state trough concentration in the current study (1075 ng/mL) was 
sufficient to produce the analgesic effect. In elderly people, a reduced dose is indicated for patients 
with impaired renal function8). However, there is no data about pharmacokinetics of pregabalin in 
dogs with renal impairment. No pregabalin accumulation was seen in this study, supporting the safety 
of pregabalin in non-azotaemic dogs. 
The main limitation of this study is the small sample size. The small number of dogs recruited 
in approximately 7 months could be because the incentive to dog owners (free treatment after 
completing the study) was modest compared to the limiting high cost of the MRI. Additionally, dogs 
already on gabapentinoids could not participate unless the treatment was withdrawn, and this was not 
always possible or ethical in severely affected dogs. Another limitation of this study was that the 
sedation observed in two dogs was not objectively quantified nor assessed for all dogs. Sedation can 
alter sensory thresholds slowing the reaction time (Gustorff et al., 2001). However, if sedation would 
have affected sensory thresholds, a generalized altered sensory threshold should have been found for 
all stimuli applied, not just in one region with specific stimuli types. 
Finally, a control group with a healthy cohort of Cavalier King Charles Spaniels would have 
been needed to compare baseline thresholds. The high prevalence of this disease (Thofner et al., 
2015) and financial constraints of imaging in dogs with no clinical signs made this not possible. 
Conclusions 
This is the first double-masked crossover placebo control clinical trial in dogs with NeP to 
investigate the efficacy of pregabalin on daily pain scores recorded by dog owners. Pregabalin also 
significantly reduced mechanical hyperalgesia and cold hyperalgesia and allodynia compared to 
placebo. Pregabalin was well tolerated with mild sedation in few cases. A larger sample is needed to 
confirm effect of pregabalin on other outcome variables. 
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https://www.nice.org.uk/guidance/cg173/resources/neuropathic-pain-in-adults-pharmacological-
management-in-nonspecialist-settings-pdf-35109750554053 (Accessed 27 June 2019). 
 
2See: British Veterinary Association. Chiari Malformation/Syringomelia Scheme. 
https://www.bva.co.uk/canine-health-schemes/cm-sm-scheme/ 
https://www.bva.co.uk/uploadedFiles/Content/Canine_Health_Schemes/CM_SM_Procedure_Notes
(1).pdf (Accessed 27 June 2019). 
 
3See: International Renal Interest Society IRIS Staging of CKD. http://www.iris-
kidney.com/guidelines/staging.html (Accessed 27 June 2019). 
 
4See: The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and 
Information Technology Unit. VICH Topic GL9 (GCP) 
 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/10/WC500004
343.pdf (Accessed 27 June 2019). 
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https://ec.europa.eu/health//sites/health/files/files/eudralex/vol5/dir_1991_412/dir_1991_412_en.pdf 
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6See: Win Episcope 2.0 http://winepi.net/uk/index.htm (Accessed 30 June 2019). 
 
7See: The R Project for Statistical Computing. https://www.r-project.org/ (Accessed 27 June 2019). 
 
8See: Package leaflet: Information for the user Lyrica 20 mg/ml mg/mL oral solution Pregabalin 
https://www.medicines.org.uk/emc/files/pil.4120.pdf (Accessed 27 June 2019). 
  
Figure legends 
 
 
Fig. 1 Group allocation during the two period crossover study and timeline of the visits. Representation 
of Visit 1, Visit 2 (treatment switch) and Visit 3 for dogs receiving pregabalin or placebo first. The 
blue line is the average plasma concentration-time curve simulated from the pharmacokinetics from 
Salazar et al. 2009. The red dots are the times at which plasma samples were obtained for measurement 
of pregabalin in the current study.  
 
 
Fig. 2 Dog allocation diagram. The two periods consisted on a 2-week treatment with non-anti-
inflammatory drug and placebo or pregabalin; then they switched treatment for another 2-week period. 
One dog was excluded on the first week of the Period 1 because she developed haemorrhagic diarrhoea 
non-related to treatment. 
 
Fig. 3 Mean and individual daily pain scores recorded by dog owners using numerical rating scale 
(NRS; from 0 [no pain] to 10 [worst pain]) based on the level of spontaneous yelping, scratching 
episodes and exercise impairment. Red triangles represent pregabalin phase daily scores with the red 
line representing the mean and blue triangles represent placebo phase daily scores with the blue line 
representing the mean value.  
 
 
Fig. 4 Box plot of the mechanical thresholds in Newton (N) obtained at baseline, placebo and 
pregabalin treatments in the different body areas. There was a significant effect of treatment group 
(P = 0.001) but the interaction treatment group and body area was not significant. MT during pregabalin 
were significantly higher than baseline and placebo (P = 0.037 and P < 0.001, respectively). Placebo 
MT were not significantly different from baseline (P = 0.097). PGB: pregabalin. 
 
Fig. 5 Cold latency at 0 °C in s obtained at baseline, placebo and pregabalin treatments in the different 
body areas. Right and left sides are display separately. Individual values are represented by the opened 
dots and solid dots are the mean proportion across all dogs. More dogs tolerated Cold (0 °C) latency for 
>1 s with pregabalin compared to baseline (P = 0.001) and placebo (P = 0.004). There were no 
significant differences between placebo and baseline (P = 0.686), or the interaction between treatment 
phase and body area (P = 0.074). PGB: pregabalin. 
 
 
Fig. 6 Cold latency at 15 °C thresholds (measured in s) obtained at baseline, placebo and pregabalin 
treatments in the different body areas. Right and left sides are display separately. Neck and humeri 
showed longer latencies on pregabalin compared to baseline grouping both side together (right and left; 
P < 0.001 for both) or placebo (P = 0.02, P = 0.0001, respectively; Fig. 6). Baseline and placebo were 
also different of each other on humeri (P = 0.001), however not on the neck (P = 0.167). Cold latency 
at 15 °C on the tibias were not significantly different between treatment phases. PGB: pregabalin.  
 
 
 
